WuXi PharmaTech boosted its revenue 15.6% last year, and China's largest CRO is expecting to match that growth in the new year, counting on steady demand for manufacturing and a larger share of the U.S. research market.
One of India's solutions to get lower-cost meds for its impoverished and uninsured--compulsory licenses--has ignited drugmakers' ire. And with an Indian committee currently assessing a batch of patented drugs as compulsory licensing candidates, the U.S. is fighting back--politely, at least so far.
Back in November, the GAVI Alliance added inactivated poliovirus vaccines to the list of products it makes available in the world's poorest countries. And with the conclusion of its tender process, UNICEF is adding its backing: The children's fund has struck a deal with Sanofi to supply the vaccine to GAVI-supported countries for as little as $1 per dose.
Eli Lilly and Chinese partner Novast have started on a new plant in China to manufacture generic versions of Lilly drugs, a bit of good news on a day when manufacturing issues had otherwise cast a shadow over the Indianapolis-based drugmaker.
Early-phase CRO Celerion is expanding its reach into South Korea, partnering up with a local hospital to run trials in the country's fast-growing market for clinical research.
Serving emerging markets generally requires local production--and that means investments in upgrades. That is the phase Eli Lilly is in with a packaging operation in São Paulo, Brazil.
With some of its larger rivals already at work on biotech knockoffs, Indian drugmaker Lupin is on the hunt for partners to help shepherd it into the biosimilar fray, taking aim at top-selling treatments soon to come off patent.
Bayer already has a big footprint in China, where it's been selling drugs since the 1930s. But that footprint is about to get a bit bigger. The company is set to buy out China's Dihon Pharmaceutical Group, a company that specializes in OTC drugs--making it just the kind of pickup the German drugmaker's been scouting for.
The FDA has taken some tough action against Indian drugmakers like Ranbaxy Laboratories. It has a dozen inspectors stationed in India and will beef that up to 19. But the agency doesn't have it out for Indian drugmakers, FDA Commissioner Margaret Hamburg insists. Its actions there just reflects that India has become one of the biggest links in the global supply chain.
China has yet to leverage any formal penalties on GlaxoSmithKline for the $489 million bribery scandal that broke there last summer. But punishment may be on the way from GSK's home base.